Sun Pharma's Dementia Drug Rivastigmine Banned in China
In 2024, the USFDA issued a warning letter to Sun Pharma alleging "significant violations" of "current good manufacturing practice" regulations for pharmaceuticals made at the same production site in India.
Written By : sheeba farhat
Published On 2026-01-27 08:57 GMT | Update On 2026-01-27 08:57 GMT
Advertisement
New Delhi: China's medicine regulator has ordered a halt to the import, sale and usage of a drug used to treat dementia associated with Alzheimer's disease made by India's Sun Pharmaceutical Industries, according to an announcement posted on Monday.
The National Medical Products Administration said a recent remote inspection found shortcomings in the company's production processes, including in the prevention of contamination and the quality management department's fulfillment of duties.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.